Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 13, 2011, covering events occurring on December 7, 2011. The filing details the results of the Company's 2011 Annual Meeting of Stockholders and subsequent Board of Director actions regarding executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and compensation matters rather than financial performance.
Material Changes and Corporate Actions
Director Elections
Stockholders elected eight directors to serve until the 2012 annual meeting. All nominees received significant support, though Derace L. Schaffer, M.D., received a higher number of withheld votes (3,377,979) compared to other nominees.
- John Gill: 16,250,760 votes for; 591,386 withheld.
- Brian A. Markison: 16,200,206 votes for; 641,940 withheld.
- Joel McCleary: 16,238,110 votes for; 604,036 withheld.
- Eric I. Richman: 16,234,470 votes for; 607,676 withheld.
- Jeffrey W. Runge, M.D.: 16,240,385 votes for; 601,761 withheld.
- Mitchel Sayare, Ph.D.: 16,241,285 votes for; 600,861 withheld.
- Derace L. Schaffer, M.D.: 13,464,167 votes for; 3,377,979 withheld.
- Steven St. Peter, M.D.: 16,256,035 votes for; 586,111 withheld.
Broker non-votes totaled 21,852,775 for all director elections.
Auditor Ratification
Stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2011, with 37,873,582 votes for, 714,320 against, and 107,019 abstentions.
Executive Compensation
The Board approved compensation for President and CEO Eric Richman under the 2007 Long-Term Compensation Plan:
- Bonus Option: 91,121 shares, vesting in full on the first anniversary.
- Standard Option: 150,000 shares, vesting 25% annually starting the first anniversary.
- Restricted Stock: 75,000 shares, vesting in full on the third-month anniversary.
- Exercise Price: $1.16 per share (closing price on NYSE Amex on grant date).
Cash bonuses were also approved for executive officers, including Eric Richman and Tom Fuerst, consistent with the 2011 Bonus Program.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, or specific risk factors. The document is limited to reporting the outcomes of the annual meeting and specific compensation grants.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 316,121 new equity awards granted to the CEO.
- Review the 2011 Bonus Program terms to confirm the material consistency of the cash bonuses mentioned.
- Monitor the voting trends for Derace L. Schaffer, M.D., given the significantly higher number of withheld votes compared to other directors.
- Confirm the vesting schedules and exercise prices for the new equity grants in the context of the current stock price.